{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103532","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.644515+00:00","generated_at":"2026-05-17T20:18:39.468940+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MannKind Q2 revenue $76.5M (+6% YoY); Afrezza sBLA for pediatric population submitted","bullets":["Total revenues $76.5M, up 6% YoY; net income $0.7M versus net loss $2.0M in Q2 2024.","Afrezza sales $18.3M (+13% YoY); royalties from Tyvaso DPI $31.2M (+22%).","Non-GAAP net income $13.9M ($0.05/share) vs $14.3M ($0.05) in Q2 2024.","Submitted sBLA for Afrezza in pediatric patients (ages 4-17); FDA decision expected early Q4 2025.","ICoN-1 trial of MNKD-101 enrollment ahead of schedule; interim target of 100 patients expected early Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103532","json":"https://secwatch.observer/filing/0000950170-25-103532.json","markdown":"https://secwatch.observer/filing/0000950170-25-103532.md","text":"https://secwatch.observer/filing/0000950170-25-103532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000095017025103532/0000950170-25-103532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000095017025103532/mnkd-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:18:39.468940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}